Significant Contract Modifications ($10M+) — July 23, 2026

Booz Allen Hamilton received a $1.07 billion defense contract from GSA, signaling strong demand for its services and a potential competitive moat given the sole-source nature.

Air Products secured a $120.3 million firm-fixed-price delivery order from NASA for helium support at Kennedy Space Center, with $120.2 million already outlayed, indicating high payment certainty and a stable multi-year revenue stream through 2025.

IAVI's $95.6 million firm-fixed-price contract for Marburg and Sudan ebolavirus vaccine development transfers cost overrun risk to the nonprofit, with only $47.3M outlayed and technical milestones critical for continued funding.

IAVI's $95.6M firm-fixed-price contract for vaccine R&D transfers cost overrun risk to the nonprofit, which has limited financial buffers compared to for-profit biotechs.

The Booz Allen Hamilton $1.07B contract from GSA may face protest risk if competitors challenge the sole-source award, potentially delaying revenue recognition.

Booz Allen Hamilton's $1.07B contract represents 83% of total digest value, indicating high concentration risk in a single award for the digest's aggregate.

Booz Allen Hamilton's $1.07B defense contract from GSA signals potential for further defense services growth, especially given the sole-source nature indicating a competitive moat.

Air Products' $120.3M NASA contract for helium support at Kennedy Space Center highlights stable government demand for industrial gases, with potential for option exercises through 2025.

IAVI's $95.6M BARDA contract for filovirus vaccine development could lead to additional government funding if milestones are met, though execution risk is high.

Booz Allen Hamilton's $1.07B sole-source defense contract from GSA underscores the government's reliance on established contractors for critical services, creating durable revenue streams.

Air Products' $120.3M NASA contract for helium support at Kennedy Space Center reflects sustained investment in space launch infrastructure, benefiting industrial gas suppliers.

IAVI's $95.6M BARDA contract for filovirus vaccines demonstrates ongoing government commitment to biodefense R&D, though fixed-price terms shift risk to contractors.

{"entity" => "Booz Allen Hamilton", "reason" => "Received $1.07B sole-source defense contract from GSA; potential protest risk and concentration concern.", "trigger" => "GAO protest filing deadline (10 days from award date)"}

{"entity" => "Air Products and Chemicals", "reason" => "NASA helium contract runs through September 2025; option exercises will indicate revenue upside.", "trigger" => "Option exercise announcements or new delivery orders under the contract"}

{"entity" => "IAVI", "reason" => "BARDA contract for vaccine R&D has high execution risk; milestone achievements critical for continued funding.", "trigger" => "Technical milestone reports or option exercise decisions by HHS/BARDA"}